MetaCap

Biofrontera Inc. (BFRI)

NASDAQ: BFRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.53-0.04 (-7.02%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BFRI stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.26
52-week range
0.53 – 1.66
Day range
0.53 – 0.5882
Volume / Avg
195.91K / 429.04K
Beta
—

52-week range

$0.53$1.66

BFRI stock today

Shares of Biofrontera (BFRI) finished lower on Nov 20 at $0.53, a drop of 7.02% or $0.04 per share, versus the S&P 500's 3.70% decline. Trading was light, with 195.91K shares changing hands, about 46% of the average daily volume. Shares are 68.1% below their 52-week high of $1.66, set on Sep 8, 2026 and 0.0% above the 52-week low of $0.53, near the bottom of the past year's range.

BFRI is down 7.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 28.4%. Biofrontera has posted a net loss over the last twelve months (EPS of -$0.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Biofrontera

Company profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Hermann Luebbert Ph.D.
Headquarters
Woburn, MA
Employees
84
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Biofrontera generated $41.7 million in revenue, up 11.7% from fiscal 2024, its 5th consecutive year of revenue growth. Biofrontera reported a net loss of $10.5 million, compared with a loss of $17.8 million a year earlier. Operating margin was -27.2%.

Biofrontera annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$41.70M$37.32M$34.07M$28.67M$24.10M
Growth+11.75%+9.54%+18.82%+18.98%+27.86%
Net income$-10.54M$-17.76M$-20.13M$-640.00K$-37.71M
EPS (diluted)$-1.04$-3.22$-13.02$-0.61$-4.28

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$6.00+1032.08%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.59 vs —

BFRI news

All BFRI news

Biofrontera peers

Health Care sector
BFRI peer companies
CompanyPrice% ChgMarket capCompare
CMMBChemomab Therapeutics Ltd. ADR1.19+4.39%$9.58Mvs BFRI
RADXRadiopharm Theranostics Limited ADR0.6304-9.71%$9.90Mvs BFRI
ASBPAspire-Lakewood Holdings Inc.7.13-5.44%$10.00Mvs BFRI
GDTCCytoMed Therapeutics Limited0.755-2.33%$9.01Mvs BFRI
CALCCalciMedica Inc.1.26+7.69%$8.69Mvs BFRI
AEONAEON Biopharma Inc. Class A0.123-7.59%$10.35Mvs BFRI
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs BFRI
BIVIBioVie Inc. Class A0.80-12.07%$8.58Mvs BFRI

Indexes, lists and sector

Biofrontera stock FAQ

What is Biofrontera's stock price today?

BFRI last traded at $0.53 as of Nov 20, 4:00 PM EST, down 7.02% on the day. Prices are delayed at least 15 minutes.

Does Biofrontera pay a dividend?

No. Biofrontera does not currently pay a regular cash dividend.

Who is Biofrontera's CEO?

Dr. Hermann Luebbert Ph.D. is the chief executive officer of Biofrontera Inc., which has about 84 employees.

Has BFRI ever split its stock?

Yes. The most recent BFRI stock split was a 1-for-20 split on Jul 5, 2023.

What is the BFRI 52-week high?

The 52-week high for BFRI is $1.66 and the 52-week low is $0.53. The stock is currently 68.1% below its high.

Compare BFRI